Ondine Biomedical (FRA:VF5) Long-Term Debt: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VF5 Ondine Biomedical Inc FRA:VF5
38 GF Score
Price €0.13
GF Value €0.09
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Ondine Biomedical Long-Term Debt?

Ondine Biomedical FRA:VF5 -10.67% 38 Long-Term Debt is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:VF5 with a GF Score™ of 38/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Ondine Biomedical's Long-Term Debt for the quarter that ended in Dec. 2025 was €0.00 Mil.

Ondine Biomedical  (FRA:VF5) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ondine Biomedical Long-Term Debt Related Terms

Ondine Biomedical Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Ondine Biomedical's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ondine Biomedical Long-Term Debt Chart

Ondine Biomedical Annual Data
Trend Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ondine Biomedical Semi-Annual Data
Jun09 Dec09 Jun10 Dec10 Jun11 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:VF5
38GF Score
Ondine Biomedical Inc FRA:VF5
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.00 Mil mean?
Ondine Biomedical (FRA:VF5) has a Long-Term Debt of €0.00 Mil as of Dec. 2025.
Is Ondine Biomedical's Long-Term Debt too high?
Ondine Biomedical's current Long-Term Debt is €0.00 Mil. Overall, Ondine Biomedical has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Long-Term Debt compare to VRTX and REGN?
Ondine Biomedical's Long-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Ondine Biomedical's current Long-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.13 — trading 48.9% above its estimated fair value. The current Long-Term Debt is €0.00 Mil. Ondine Biomedical's overall GF Score™ is 38/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current Long-Term Debt is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?

Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued. The current stock price of €0.13 is trading 48.9% above its estimated GF Value™ of €0.09. GuruFocus considers Ondine Biomedical to be Significantly Overvalued.

Key valuation signals for FRA:VF5:

  • Long-Term Debt: €0.00 Mil
  • GF Value™: €0.09 vs. price of €0.13 (48.9% above fair value)
  • GF Score™: 38/100 with 9 warning signs

No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ondine Biomedical Business Description

Other Exchanges OBIMF:USAOBI:UK
Address 1100 Melville Street, Suite 888, Vancouver, BC, CAN, V6E4A6
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
38GF Score

Get the complete analysis for FRA:VF5

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.13
Price
€0.09
GF Value